No Data
First Mpox Case Linked to African Outbreak Reported in U.S.
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Chimerix Analyst Ratings
Chimerix's Dordaviprone Shows Promising Efficacy in H3 K27M-mutant Diffuse Glioma With $11 Price Target
Press Release: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript Summary